Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1986 2
1988 1
1989 2
1994 1
1995 1
1998 1
1999 1
2000 3
2002 1
2003 3
2005 5
2006 2
2007 2
2008 4
2009 2
2010 5
2011 5
2012 4
2013 6
2014 4
2015 1
2016 5
2017 1
2018 2
2019 4
2020 3
2021 5
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Harrington KJ, et al. JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147. JAMA Oncol. 2023. PMID: 37022706 Free PMC article.
IMPORTANCE: There remains an unmet need to improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). ...Eligible participants were aged 18 years or older and had platinum-refractory or …
IMPORTANCE: There remains an unmet need to improve clinical outcomes in patients with recurrent or metastatic squamous cell …
Squamous cell carcinoma of the thyroid gland: primary or secondary disease?
Syed MI, Stewart M, Syed S, Dahill S, Adams C, McLellan DR, Clark LJ. Syed MI, et al. J Laryngol Otol. 2011 Jan;125(1):3-9. doi: 10.1017/S0022215110002070. Epub 2010 Oct 18. J Laryngol Otol. 2011. PMID: 20950510 Review.
OBJECTIVE: To review the aetiopathogenesis, clinical characteristics, immunohistochemical profile, prognosis and treatment options for primary thyroid squamous cell carcinoma, and to compare it with squamous cell carcinoma metastatic …
OBJECTIVE: To review the aetiopathogenesis, clinical characteristics, immunohistochemical profile, prognosis and treatment options for prima …
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Specenier P, Vermorken JB. Specenier P, et al. Expert Rev Anticancer Ther. 2011 Apr;11(4):511-24. doi: 10.1586/era.11.20. Expert Rev Anticancer Ther. 2011. PMID: 21504318 Review.
The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR). ...In the EXTREME trial, the addition of cetuximab to platinum/5-fluorouracil as first-line treatment of recurrent/metastatic squamo …
The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR). .. …
Epidermolysis bullosa: Advances in research and treatment.
Prodinger C, Reichelt J, Bauer JW, Laimer M. Prodinger C, et al. Exp Dermatol. 2019 Oct;28(10):1176-1189. doi: 10.1111/exd.13979. Epub 2019 Aug 8. Exp Dermatol. 2019. PMID: 31140655 Free PMC article. Review.
Current clinical research activities at the EB House Austria include newly developed candidate substances that have emerged out of our translational research initiatives as well as already commercially available medications that are applied in off-licensed indications. Squamou …
Current clinical research activities at the EB House Austria include newly developed candidate substances that have emerged out of our trans …
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes.
Peyrade F, Borel C, Daste A, Even C, Saada-Bouzid E, Guigay J. Peyrade F, et al. Curr Opin Oncol. 2021 May 1;33(3):160-167. doi: 10.1097/CCO.0000000000000738. Curr Opin Oncol. 2021. PMID: 33782359 Review.
PURPOSE OF REVIEW: Worldwide, head and neck carcinomas account for 5% of all malignancies. Two-thirds of patients relapse after initial multimodal therapy. Until early 2010, the median overall survival (OS) of metastatic patients was about 10 months. ...SUMMARY: Thi …
PURPOSE OF REVIEW: Worldwide, head and neck carcinomas account for 5% of all malignancies. Two-thirds of patients relapse after initial mult …
Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher.
Szturz P, Vermorken JB. Szturz P, et al. Oral Oncol. 2020 Feb;101:104492. doi: 10.1016/j.oraloncology.2019.104492. Epub 2019 Dec 11. Oral Oncol. 2020. PMID: 31837576 Review.
In recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN), the armamentarium of systemic anti-cancer modalities continues to grow in parallel with innovations in and better integration of local approaches. ...In oligometas …
In recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN), the armamentarium of sy …
Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients.
Boyd K, Shea SM, Patterson J. Boyd K, et al. Wien Med Wochenschr. 2013 Aug;163(15-16):372-5. doi: 10.1007/s10354-013-0213-5. Epub 2013 Jun 26. Wien Med Wochenschr. 2013. PMID: 23800851 Review.
Survival of solid organ transplant patients has been prolonged, leading to increased incidence of non-melanoma skin cancers. Metastatic squamous cell carcinoma is an increasing problem in these patients. This paper reviews the evidence available for th …
Survival of solid organ transplant patients has been prolonged, leading to increased incidence of non-melanoma skin cancers. Metastatic …
Recurrent head and neck cancer: current treatment and future prospects.
Specenier PM, Vermorken JB. Specenier PM, et al. Expert Rev Anticancer Ther. 2008 Mar;8(3):375-91. doi: 10.1586/14737140.8.3.375. Expert Rev Anticancer Ther. 2008. PMID: 18366286 Review.
Recurrent and metastatic squamous cell carcinoma of the head and neck still carries a poor prognosis. ...In addition, the response rate nearly doubled with this approach, which has great promise for the treatment of symptomatic disease. There is now a …
Recurrent and metastatic squamous cell carcinoma of the head and neck still carries a poor prognosis. ...In addi …
Diagnostic and therapeutic management of cancer of an unknown primary.
Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Pavlidis N, et al. Eur J Cancer. 2003 Sep;39(14):1990-2005. doi: 10.1016/s0959-8049(03)00547-1. Eur J Cancer. 2003. PMID: 12957453 Review.
The following clinicopathological entities have been recognised: (i) metastatic CUP primarily to the liver or to multiple sites, (ii) metastatic CUP to lymph nodes including the sub-sets involving primarily the mediastinal-retroperitoneal, the axillary, the cervical …
The following clinicopathological entities have been recognised: (i) metastatic CUP primarily to the liver or to multiple sites, (ii) …
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL. Gillison ML, et al. Oncologist. 2022 Mar 4;27(2):e194-e198. doi: 10.1093/oncolo/oyab036. Oncologist. 2022. PMID: 35641218 Free PMC article.
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the …
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of …
78 results